Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Ostex International, Inc. (NasdaqNM:OSTX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Reports
Recent Events
Aug 23Price hit new 52-week high ($3.80)
Location
2203 Airport Way South, Suite 400
Seattle, WA 98134
Phone: (206) 292-8082
Fax: (206) 292-8625
Employees (last reported count): 45
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Medical Equipment & Supplies
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 46%
·Institutional: 12% (22% of float)
(17 institutions)
·Net Inst. Selling: 51.0K shares (+3.45%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Ostex International, Inc. is engaged in the discovery and commercialization of products associated with osteoporosis and other collagen-related diseases. The Company believes that its lead product, the OSTEOMARK test, now available in multiple test formats, incorporates patented technology in the area of bone resorption measurement. The Company is the exclusive licensee of the Osteomark technology, known clinically as the NTx test, which is available in multiple formats that can aid in healthcare decision-making at early menopause and beyond. The Osteomark test is a non-invasive test that quantitatively indicates the level of bone resorption. In addition, the Company's Osteomark test aids clinicians in monitoring the effects of antiresorptive therapies in postmenopausal women and those diagnosed with osteoporosis, in a matter of three months versus one to two years with conventional technology.
More from Market Guide: Expanded Business Description

Financial Summary
Ostex International, Inc. is engaged in the discovery and commercialization of products associated with osteoporosis and other collagen-related diseases. For the six months ended 6/30/01, total revenues rose 23% to $3 million. Net loss rose 9% to $1.4 million. Revenues reflect increased shipments of NTx Serum kits and Urine kits. Higher loss reflects cost associated with inventory adjustments and costs associated with the NTx Point of Care device.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Thomas Bologna, 52
Chairman, Pres, CEO
$466K
Thomas Broderick, 52
VP, Patent and Gen. Counsel
195K
Michael Perry, 56
VP of Sales and Marketing
115K
J. Daniel Clemens, 44
VP, Product Devel.
122K
Nancy Mallinak, 39
VP, Regulatory and Clinical Affairs
119K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:OSTXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 26-Mar-2001
$1.00 
Recent Price$2.92 
52-Week High
on 23-Aug-2001
$3.80 
Beta1.73 
Daily Volume (3-month avg)29.2K
Daily Volume (10-day avg)114.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+29.8%
52-Week Change
relative to S&P500
+74.1%
Share-Related Items
Market Capitalization$36.6M
Shares Outstanding12.5M
Float6.80M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.69 
Earnings (ttm)-$0.17 
Earnings (mrq)-$0.04 
Sales (ttm)$0.49 
Cash (mrq)$0.39 
Valuation Ratios
Price/Book (mrq)4.25 
Price/EarningsN/A 
Price/Sales (ttm)5.97 
Income Statements
Sales (ttm)$6.12M
EBITDA (ttm)-$2.59M
Income available to common (ttm)-$2.13M
Profitability
Profit Margin (ttm)-34.8%
Operating Margin (ttm)-42.5%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-18.45%
Return on Equity (ttm)-21.90%
Financial Strength
Current Ratio (mrq)5.01 
Debt/Equity (mrq)0.19 
Total Cash (mrq)$4.95M
Short Interest
As of 8-Aug-2001
Shares Short56.0K
Percent of Float0.8%
Shares Short
(Prior Month)
56.0K
Short Ratio4.00 
Daily Volume14.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.